John Wiley & Sons, Inc. (WLYB) Stock Price & Analysis
John Wiley & Sons, Inc. (WLYB) closed at USD 54.08 on Thursday, October 22, 2026, up 0.63% on the day. The US market is currently closed (pre-market); this is not a live price.
The prior close was USD 53.74; the Oct 22, 2026 session ranged USD 54.08–54.08 on volume of 156 shares. Market capitalization is $2.74B, with a 52-week range of USD 29.62–55.51 (NYQ). Source: Nexqual, retrieved October 23, 2026 at 10:34 UTC.
Also available as compact Markdown for AI agents: nexqual.com/WLYB.md
Key facts (WLYB)
- Last four reported quarters (through Jul 31, 2026): revenue $1.67B, net income $198M (11.9% margin), free cash flow $240M (SEC filings).
- Valuation: P/E 13.8x (avg 19.1x at the last 2 fiscal year-ends), EV/EBITDA 10.0x, net debt $1.18B.
- Analysts: None.
- Total return with dividends: 1Y +51.0% vs S&P 500 +14.9%; 5Y +20.3% vs S&P 500 +80.3%.
- Next earnings: 2026-12-03, EPS estimate USD —, revenue estimate $448M.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (WLYB)
| USD | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $2.08B | $2.02B | $1.87B | $1.68B | $1.68B | $1.67B |
| Gross profit | $1.38B | $1.33B | $1.29B | $1.25B | $1.25B | — |
| Operating income | $219M | $55.9M | $52.3M | $221M | $277M | $249M |
| Net income | $148M | $17.2M | -$200M | $84.2M | $222M | $198M |
| EPS (diluted) | $2.62 | $0.31 | -$3.65 | $1.53 | $4.16 | — |
| Free cash flow | $250M | $196M | $132M | $141M | $209M | $240M |
| Gross margin | 66.4% | 65.7% | 69.0% | 74.3% | 74.3% | — |
| Operating margin | 10.5% | 2.8% | 2.8% | 13.2% | 16.5% | 14.9% |
| Net margin | 7.1% | 0.9% | -10.7% | 5.0% | 13.2% | 11.9% |
| Revenue growth | +7.3% | -3.0% | -7.3% | -10.4% | -0.1% | — |
| Cash + short-term investments | $100M | $107M | $83.2M | $85.9M | $75.6M | — |
| Total debt | $787M | $748M | $775M | $799M | $683M | — |
Fiscal years end Apr. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Jul 31, 2026) (WLYB)
P/E 13.8x · P/S 1.6x · EV/EBITDA 10.0x · EV/Sales 2.4x · P/FCF 11.4x · P/B 3.4x · FCF yield 8.75% · Earnings yield 7.23% · Dividend yield (paid, TTM) 2.68% · Buyback yield (TTM) 3.71% · Net debt $1.18B · EV $3.93B
P/E at fiscal year-ends: Apr 2026 9.9x, Apr 2025 28.3x.
Analysts (WLYB)
Consensus None.
Total return (dividends reinvested) (WLYB)
| 1Y (from 2025-10-23) | 5Y (from 2021-10-18) | |
|---|---|---|
| Total return | +51.0% | +20.3% |
| S&P 500 (SPY) | +14.9% | +80.3% |
| Per year | +51.2% | +3.8% |
| Volatility (annualized) | 41.7% | 37.7% |
| Max drawdown | -21.5% (Oct 2025→Feb 2026) | -43.7% (Mar 2022→Nov 2023) |
WLYB revenue by business segment (quarter ended Jul 31, 2026)
| Line | Revenue | Share of total | YoY |
|---|---|---|---|
| Research | $293.5M | 76.0% | +4.2% |
| Learning | $92.9M | 24.0% | -19.3% |
| Total revenue | $386.4M | 100% | — |
WLYB revenue by product line (quarter ended Jul 31, 2026)
| Line | Revenue | Share of total | YoY |
|---|---|---|---|
| Research Publishing | $258.9M | 67.0% | +11.7% |
| Professional | $48.1M | 12.5% | -19.3% |
| Academic | $44.7M | 11.6% | -19.3% |
| Research Solutions | $34.6M | 9.0% | -30.6% |
| Total revenue | $386.4M | 100% | — |
WLYB revenue by region (fiscal year ended Apr 30, 2026)
| Line | Revenue | Share of total | YoY |
|---|---|---|---|
| United States | $854.5M | 51.0% | +0.7% |
| United Kingdom | $490.4M | 29.3% | -1.7% |
| Germany | $192.3M | 11.5% | +5.1% |
| Other Countries | $139.3M | 8.3% | -5.3% |
| Total revenue | $1.68B | 100% | — |
As tagged by the company in its SEC 10-Q / 10-K filings (XBRL).
WLYB company outlook (results filed Sep 3, 2026)
- “Metric Fiscal 2025 Fiscal 2026 Fiscal 2027 Outlook Organic Revenue Growth* Low-to-mid single digit growth (Research: mid-single digit growth) Adjusted EBITDA Margin 24.0% 26.2% 26.5% to 27.5% Adjusted EPS $3.64 $4.19 $4.60 to $5.05 Free Cash Flow $126M $195M $205M *Organic Revenue Growth" excludes the effects of the Emerald acquisition and currency movements.”
Quoted word-for-word from the SEC 8-K results press release.
WLYB analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Oct 2026) | — | — | — | $448.0M | — |
| Next quarter (ends Jan 2027) | — | — | — | $438.9M | — |
| Current fiscal year (ends Apr 2027) | — | — | — | $1.75B | — |
| Next fiscal year (ends Apr 2028) | — | — | — | $1.81B | — |
Key Statistics (as of October 23, 2026 at 10:34 UTC)
| Price | USD 54.08 |
|---|---|
| Change | ▲ 0.63% (up) |
| Previous Close | USD 53.74 |
| Open | USD 54.08 |
| Day Range | USD 54.08 – 54.08 |
| 52-Week Range | USD 29.62 – 55.51 |
| Volume | 156 shares |
| Market Cap | $2.74B |
| Exchange | NYQ |
Technical Analysis (WLYB)
Nexqual's technical model rates WLYB "BUY" based on 5 bullish and 2 bearish signals across 127 daily candles, as of October 23, 2026 at 10:34 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 76.31 (overbought) |
| vs SMA50 | Above (USD 50.48) |
| MACD | 1.1 (positive) |
Analyst Ratings (WLYB)
Wall Street analysts rate WLYB "None", per Nexqual as of October 23, 2026 at 10:34 UTC.
| Consensus Rating | None |
|---|
Earnings (WLYB)
| Next Earnings Date | 2026-12-03 |
|---|---|
| Revenue Estimate | $448.00M |
Source: Nexqual, October 23, 2026 at 10:34 UTC.
Financials & Fundamentals (WLYB)
| Total Revenue | $1.67B |
|---|---|
| Revenue Growth (latest quarter, YoY) | -2.60% |
| Gross Margin | +74.60% |
| Operating Margin | +7.29% |
| Profit Margin | +11.90% |
| ROE | +25.91% |
| Debt / Equity | 1.73 |
| Current Ratio | 0.64 |
| Total Cash | $106.65M |
| Total Debt | $1.38B |
| Free Cash Flow (last four quarters to Jul 2026, SEC 10-Q / 10-K) | $239.89M (14.4% of revenue) |
Source: Nexqual, October 23, 2026 at 10:34 UTC.
Financial Health Score (WLYB)
Nexqual rates John Wiley & Sons, Inc.'s overall financial health "Mixed" across five dimensions, as of October 23, 2026 at 10:34 UTC.
| Growth | Weak — Revenue -0% YoY (annual), declining |
|---|---|
| Profitability | Strong — Gross margin 75%, operating 7% (last 12 months) |
| Balance Sheet | Critical — $106M cash and investments vs $1.29B debt (Jul 2026, SEC) |
| Cash Flow | Solid — FCF $240M (last 4 quarters to Jul 2026, SEC), 14% margin |
| Efficiency | Strong — ROE 26%, ROA 6.2% |
Ownership (WLYB)
| Insider Ownership | +94.23% |
|---|---|
| Institutional Ownership | +2.64% |
| Shares Outstanding | 8.76M |
| Float | 37.95M |
| Short % of Float | +0.16% |
Source: Nexqual, October 23, 2026 at 10:34 UTC.
Leadership (WLYB)
John Wiley & Sons, Inc. is led by Matthew S. Kissner, President, CEO & Employee Director, per Nexqual as of October 23, 2026 at 10:34 UTC.
| President, CEO & Employee Director | Matthew S. Kissner |
|---|---|
| Non-Executive Chairman | Jesse Caleb Wiley |
| Executive VP & CFO | Craig Albright |
| Executive Vice President of Technology & Operations | Andrew Weber |
| Senior Vice President of Business Transformation | Christopher F. Caridi |
Major Backers & Investors (WLYB)
Notable institutional backers of John Wiley & Sons, Inc. include Morgan Stanley, Pfg Investments, LLC , Royal Bank of Canada, according to Nexqual as of October 23, 2026 at 10:34 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Morgan Stanley | 0.74% |
| Pfg Investments, LLC | 0.61% |
| Royal Bank of Canada | 0.32% |
| Cannell & Spears LLC | 0.23% |
| Caldwell Sutter Capital, Inc. | 0.14% |
| Neuberger Berman Group, LLC | 0.12% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 0.24% |
| Geode Capital | 0.12% |
Source: Nexqual, October 23, 2026 at 10:34 UTC.
From John Wiley & Sons, Inc.'s Latest SEC 10-K Filing (filed 2026-06-24)
Key Strengths & Strategy (as disclosed to the SEC)
- Research Exchange (ReX) is Wiley's proprietary end-to-end manuscript submission and peer review platform, designed to streamline the publishing workflow for authors, editors, and reviewers.
- Digital books are delivered to intermediaries and aggregators, including Amazon, Apple, and Google, for sale to individuals, libraries, or distinct communities in various industry-standard or custom formats.
- AI and data analytics is our emerging growth engine, leveraging our proprietary content, data, and partnership ecosystem for corporate models and applications.
Partnerships
- As with our subscription portfolio, a number of the Gold Open Access Journals are published under contract for, or in partnership with, prestigious societies, including the American Geophysical Union, the American Heart Association, and the British Ecological Society.
- Through our alliance with The Cochrane Collaboration, we publish The Cochrane Library, a premier source of high-quality independent evidence to inform healthcare decision-making.
Legal & Regulatory Risks (Item 1A, quoted)
- Changes in laws, tariffs, and regulations, including regulations related to open access, could adversely impact our consolidated financial position and results of operations.
- We may in the future discover material weaknesses in our system of internal financial and accounting controls and procedures that could result in a material misstatement of our financial statements.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| TDAY | USA TODAY Co., Inc. | USD 7.04 | ▲ 1.73% |
| SCHL | Scholastic Corporation | USD 39.01 | ▲ 0.88% |
| PSO | Pearson, Plc | USD 18.39 | ▲ 1.32% |
| NYT | New York Times Company (The) | USD 69.42 | ▲ 0.81% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 23, 2026 at 10:34 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt